Skip to content

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
AbbVie logo
AbbVieABBV
$3.56B+155%
Bausch + Lomb logo
Bausch + LombBLCO
-$68M+49.6%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
-$30.47M-43.4%
Glaukos logo
GlaukosGKOS
Schering-Plough logo
Schering-PloughSGP

Other financials

Income statement

See full
Revenue$19.7M+12.5%
Gross profit$17.0M+12.5%
Operating income-$12.4M+10.4%
Net income-$13.0M+8.3%
EPS (diluted)-$0.24+14.3%

Balance sheet

See full
Cash & equivalents$85.0M-21.9%
Total debt$40.9M+1.1%
Total equity$53.9M-30.6%
Total assets$109.7M-15.4%

Cash flow

See full
Operating cash flow-$7.0M+39.4%
CapEx$60.0K

Valuation

See full
Market cap$294.9M+34.2%
Enterprise value$250.83M+58.0%
P/S3.7×+0.8×

Profitability

See full
Gross margin86.2%+0.5pp
Operating margin-44.8%-10.2pp
Net margin-46.8%-9.6pp
FCF margin-31.9%+0.2pp

Returns & leverage

See full
Return on equity-56.6%+4.3pp
Debt / equity0.8×+0.2×
Current ratio5.9×-4.6×

Where this comes from

Calculated from Sight Sciences, Inc.’s reported figures.

The official record: Sight Sciences, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sight Sciences, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sight Sciences, Inc.'s free cash flow?
Sight Sciences, Inc. (SGHT) reported free cash flow of -$7.09M in Q1 2026.
How has Sight Sciences, Inc.'s free cash flow changed year-over-year?
Sight Sciences, Inc.'s free cash flow increased by 38.9% year-over-year, from -$11.61M to -$7.09M.
What is the long-term trend for Sight Sciences, Inc.'s free cash flow?
Over 4 years (2021 to 2025), Sight Sciences, Inc.'s free cash flow has grown at a -13.5% compound annual growth rate (CAGR), from -$53.35M to -$29.92M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.